Looks like two presentations end of March 2020 at ACC/WCC 2020:
https://accscientificsession.acc.org/Information-Pages/future-meetings
1315-168 / 168 - THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL*
https://www.abstractsonline.com/pp8/#!/8992/presentation/23270
1080-05 - EPIGENETIC READER INHIBITOR APABETALONE (RVX-208) COUNTERS PROINFLAMMATORY HYPERACTIVATION OF CD14+ MONOCYTES FROM PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
https://www.abstractsonline.com/pp8/#!/8992/presentation/12275